Genmab A/S (OTCMKTS:GNMSF) Posts Quarterly Earnings Results, Beats Expectations By $1.60 EPS

Genmab A/S (OTCMKTS:GNMSF) issued its earnings results on Thursday. The company reported $6.46 earnings per share for the quarter, topping analysts’ consensus estimates of $4.86 by $1.60, Zacks reports. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $290.51 on Friday. The stock has a market cap of $19.20 billion, a P/E ratio of 14.58 and a beta of 0.95. The stock’s fifty day moving average is $294.54 and its 200 day moving average is $242.24. Genmab A/S has a one year low of $170.00 and a one year high of $336.45.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.